Blood Cancer Diagnostics Market Size & Share 2026-2035

Blood Cancer Diagnostics Market Size

The global blood cancer diagnostics market was valued at USD 13.8 billion in 2025 and is projected to grow from USD 14.7 billion in 2026 to USD 26.6 billion by 2035, expanding at a CAGR of 6.8%, according to the latest report published by Global Market Insights Inc.

This substantial growth is driven by rising prevalence of blood cancer, advancements in cancer diagnostic technologies and growing awareness and early screening programs

The market increased from USD 12.3 billion in 2023 to USD 13 billion in 2024. The increasing global burden of blood cancers is a key driver propelling the growth of the market. Hematological malignancies such as leukemia, lymphoma, and multiple myeloma are witnessing a steady rise in incidence, driven by factors including aging populations, genetic predisposition, environmental exposures, and improved disease detection. According to data published by the International Agency for Research on Cancer (IARC) through the Global Cancer Observatory (GLOBOCAN 2022), leukemia alone accounted for approximately 487,294 new cases worldwide, ranking among the top cancer types globally. The disease also resulted in around 305,405 deaths, underscoring its significant mortality burden. The high incidence and mortality rates associated with blood cancers necessitate early and accurate diagnosis to improve patient outcomes and guide personalized treatment decisions. As awareness increases and healthcare systems prioritize timely cancer detection, demand for advanced diagnostic modalities such as flow cytometry, molecular diagnostics, cytogenetics, and next-generation sequencing is rising. Furthermore, the growing adoption of routine screening, especially in high-risk and aging populations, is amplifying the volume of diagnostic testing. Collectively, the escalating prevalence of blood cancers and the clinical need for precise disease characterization are accelerating investments in diagnostic technologies, thereby driving sustained growth in the global market.

Additionally, rapid advancements in cancer diagnostic technologies are a major driver of the blood cancer diagnostics market. Innovations such as next‑generation sequencing (NGS), flow cytometry, digital PCR, and advanced cytogenetic techniques have significantly improved the accuracy, sensitivity, and speed of blood cancer detection. These technologies enable precise identification of genetic mutations, disease subtypes, and minimal residual disease, supporting early diagnosis and personalized treatment planning. Additionally, the integration of automation, artificial intelligence, and bioinformatics into diagnostic platforms is enhancing laboratory efficiency and result reproducibility. As healthcare providers increasingly adopt advanced diagnostic solutions to improve clinical outcomes and meet growing testing demands, the uptake of sophisticated blood cancer diagnostic tools continues to rise, driving sustained market growth.

Blood cancer diagnostics refers to the set of medical tests, technologies, and procedures used to detect, classify, and monitor cancers that originate in the blood‑forming tissues or immune system, including leukemia, lymphoma, and multiple myeloma. These diagnostics are essential for confirming the presence of disease, determining cancer subtype, assessing disease stage, and guiding treatment decisions.

Blood Cancer Diagnostics Market Trends

• Growing awareness about blood cancers and the importance of early diagnosis is a significant driver of the blood cancer diagnostics industry. Governments, healthcare organizations, and non‑profit bodies are actively conducting awareness campaigns to educate the public and healthcare professionals about early symptoms, risk factors, and the benefits of timely testing. Increased awareness is leading to higher patient engagement and earlier clinical consultations, thereby increasing the demand for diagnostic services.
• In parallel, the expansion of organized screening and preventive healthcare programs is supporting market growth. Hospitals and diagnostic centers are increasingly incorporating routine blood tests, complete blood counts (CBCs), and advanced hematological assessments as part of regular health check‑ups, especially for high‑risk and aging populations. These initiatives enable earlier identification of abnormalities linked to blood cancers.
• Early screening programs also improve treatment outcomes by enabling diagnosis at less advanced disease stages, which reinforces their adoption by healthcare systems. Payers and policymakers are recognizing the cost‑effectiveness of early detection in reducing long‑term treatment expenses and improving survival rates.
• As awareness efforts and screening initiatives continue to expand globally, particularly in emerging markets, the volume of diagnostic testing is expected to rise. This trend is directly contributing to sustained demand for blood cancer diagnostic technologies and services, driving overall market growth.

Blood Cancer Diagnostics Market Analysis

Based on product, the market is divided into instruments and assay kits & reagents. The assay kits & reagents segment accounted for USD 8.4 billion in 2025.

• Assay kits and reagents are essential components used in blood cancer diagnostics to detect, identify, and quantify biomarkers such as proteins, antigens, antibodies, nucleic acids, and genetic mutations associated with hematological malignancies. These products are routinely used in techniques including immunoassays, flow cytometry, molecular diagnostics, and cytogenetics. Their standardized formats, ready‑to‑use nature, and compatibility with existing laboratory instruments make them indispensable for both clinical diagnostics and research applications.
• This segment holds a leading position in terms of market share due to its high and recurring consumption across diagnostic laboratories and hospitals. Blood cancer diagnosis often requires multiple tests across disease stages screening, confirmation, prognosis, and treatment monitoring resulting in continuous demand for assay kits and reagents. Additionally, their relatively lower cost compared to diagnostic instruments and their necessity for every test conducted contribute to their widespread adoption across healthcare settings.
• For instance, Thermo Fisher Scientific offers the Oncomine Dx Target Test, widely used for detecting relevant genetic alterations in hematologic and solid tumors. These products are trusted globally due to their high accuracy, reproducibility, and regulatory approvals.
• In conclusion, the frequent usage, repeat purchasing nature, and critical role of assay kits and reagents in every stage of blood cancer testing make this segment a key contributor to overall market revenue, supporting consistent growth in the market.

Based on test type, the blood cancer diagnostics market is bifurcated into blood tests, molecular tests, imaging tests, and biopsy. The blood tests segment accounted for USD 5.3 billion in 2025.

• Blood tests are a core diagnostic approach in blood cancer evaluation, involving routine assessment of blood cell counts and related parameters to identify abnormalities linked to leukemia, lymphoma, and myeloma. They serve as the primary entry point in the diagnostic pathway, enabling early clinical suspicion and guiding subsequent confirmatory testing.
• Blood tests support market expansion by driving high testing volumes across hospitals and diagnostic laboratories. Their routine inclusion in standard clinical workflows enables broad utilization for screening, initial assessment, and longitudinal patient monitoring, ensuring recurring demand rather than episodic use.
• Cost efficiency, rapid turnaround time, and low procedural complexity further strengthen the role of blood tests. These attributes allow scalable deployment across tertiary hospitals, community healthcare facilities, and emerging markets, aligning well with healthcare systems’ focus on operational efficiency and accessibility.
• In conclusion, blood tests strengthen the growth of the blood cancer diagnostics industry by enabling early identification, continuous disease tracking, and high‑throughput testing. Their widespread adoption, repeat usage, and compatibility with automated laboratory workflows position blood tests as a cornerstone of sustainable market development.

Based on cancer type, the blood cancer diagnostics market is bifurcated into leukemia, lymphoma, and myeloma. The leukemia segment is forecasted to reach USD 11.7 billion by 2035.

• The increasing incidence of leukemia represents a key factor supporting the expansion of the diagnostics segment.
• Leukemia is a type of cancer that affects the blood and bone marrow, where blood cells are produced. It occurs when abnormal white blood cells grow uncontrollably, interfering with the body’s ability to produce normal blood cells such as red blood cells, platelets, and healthy white blood cells.
• Leukemia significantly contributes to the growth of the blood cancer diagnostics industry, due to its high incidence, need for early detection, and continuous disease monitoring requirements. As leukemia affects blood and bone marrow, diagnosis relies heavily on specialized tests such as complete blood counts, flow cytometry, molecular diagnostics, and genetic profiling, directly increasing demand for advanced diagnostic technologies.
• Furthermore, the chronic and relapsing nature of certain leukemia types requires frequent testing to track disease progression, treatment response, and remission status. This ongoing need for accurate and repeat diagnostics drives sustained utilization of laboratory instruments, reagents, and molecular testing platforms, thereby supporting long-term market expansion.
• Additionally, rising awareness levels and the expansion of screening initiatives have accelerated the adoption of leukemia diagnostic tools. Broader screening coverage and increased clinician focus on early testing have collectively contributed to steady growth across the segment.

Based on end use the blood cancer diagnostics market is categorized into hospitals, diagnostic laboratories, diagnostic imaging centers, and cancer research institutes. The hospitals segment is estimated to grow substantially to reach over USD 10.8 billion revenue size by the end of 2035.

• Hospitals are increasingly incorporating advanced diagnostic technologies and techniques to enhance both the accuracy and speed of blood cancer detection. This shift is driven by targeted investments in modern diagnostic equipment and a growing emphasis on early identification and individualized treatment strategies.
• The focus on precision diagnostics enables hospitals to support more informed clinical decisions and improve treatment planning. By prioritizing early detection and personalized care approaches, hospitals strengthen their capability to manage complex blood cancer cases effectively.
• Hospitals also benefit from integrated healthcare infrastructures that support seamless coordination across departments. This integrated model enables efficient patient management, improves care continuity, and enhances diagnostic effectiveness through multidisciplinary collaboration.
• As healthcare systems continue to evolve with a strong emphasis on precision medicine and coordinated care models, the hospital segment remains well positioned for sustained growth. Continued advancements in diagnostic technologies and a focus on improving patient outcomes are expected to further reinforce hospitals’ role in blood cancer diagnostics.

North America Blood Cancer Diagnostics Market

The North America region accounted for 46.5% of the global market in 2025. The blood cancer diagnostics industry in North America is experiencing robust expansion, driven by rising prevalence of blood cancer.

• The increasing incidence of leukemia, lymphoma, and multiple myeloma across North America is a major driver for blood cancer diagnostics demand. Aging populations and lifestyle-related risk factors continue to elevate diagnosis rates.
• Higher patient volumes have intensified the need for early and accurate disease detection. This trend is accelerating adoption of advanced diagnostic tests across hospitals and reference laboratories.
• Strong healthcare infrastructure and high per-capita healthcare spending support widespread access to sophisticated diagnostic tools. These factors collectively sustain growth in the North America market.
• The U.S. reports a steady rise in blood cancer cases, supported by aging demographics and improved disease surveillance. Leukemia and lymphoma remain among the most frequently diagnosed cancer types nationwide.
• Growing disease prevalence has increased demand for routine screening, molecular testing, and genetic profiling. Diagnostic laboratories and oncology centers are expanding capacity to address rising testing needs.
• Well-established reimbursement systems and robust oncology research activity further support technology adoption. These elements continue to fuel expansion of the U.S. market.

Europe Blood Cancer Diagnostics Market

Europe market accounted for USD 3.2 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• Advances in diagnostic technologies such as next-generation sequencing, flow cytometry, and liquid biopsy are reshaping blood cancer detection in Europe. These tools enable higher diagnostic accuracy and faster turnaround times.
• Moreover, healthcare systems across the region are increasingly integrating molecular and genomic diagnostics into clinical practice. This shift supports personalized treatment planning and improves patient outcomes.
• Regulatory support and strong public healthcare funding promote the uptake of innovative diagnostic platforms. These dynamics drive sustained growth across the European blood cancer diagnostics industry.

UK blood cancer diagnostics market is projected to experience steady growth between 2026 and 2035.

• The UK plays a leading role in adopting advanced diagnostic technologies within its healthcare system. Innovative approaches such as next-generation sequencing are increasingly used to enable detailed genetic profiling of blood cancers, while liquid biopsy techniques are gaining traction for their ability to detect cancer in a minimally invasive manner. Together, these advancements are improving diagnostic precision and supporting overall market expansion.
• The growing integration of these technologies across UK healthcare settings is helping clinicians identify blood cancers earlier and more accurately. Enhanced diagnostic capabilities contribute to better clinical decision-making and personalized treatment approaches, which in turn are strengthening demand for advanced diagnostic solutions.
• In parallel, strong momentum in research and investment activities is reinforcing market growth in the country. Long-standing support from national research organizations and charities has played a key role in advancing knowledge around blood cancers, while also accelerating progress in diagnostic and therapeutic innovation.

Asia Pacific Blood Cancer Diagnostics Market

The Asia Pacific region is projected to show a lucrative growth of about 7.2% during the forecast period.

• Public awareness of blood cancers and the benefits of early diagnosis is steadily increasing across the Asia Pacific region. Government agencies and healthcare organizations are actively advancing cancer education initiatives to improve understanding and encourage timely medical intervention.
• Additionally, the expansion of national screening programs and preventive health campaigns is improving access to diagnostic testing. These initiatives are supporting earlier disease detection and driving higher utilization of blood cancer diagnostic services across the region.
• Furthermore, ongoing improvements in healthcare infrastructure and the expansion of diagnostic laboratory networks are reinforcing these trends. Combined, these developments are contributing to rising demand and sustained growth of the market in Asia Pacific.

China market is poised to witness lucrative growth between 2026 – 2035.

• The increasing incidence of blood cancers in China is a major driver for the blood cancer diagnostics market. Factors such as population aging, environmental exposure, and lifestyle changes are contributing to a higher disease burden, necessitating greater diagnostic capacity.
• As the number of diagnosed and suspected cases rises, demand for early and accurate diagnostic testing is expanding across hospitals and specialty laboratories. This is encouraging wider adoption of advanced diagnostic tools to support timely detection and disease monitoring.
• In conclusion, to the growing prevalence, healthcare providers are prioritizing improved screening and diagnostic infrastructure. This sustained need for reliable diagnostics is directly supporting market growth and attracting investments in blood cancer testing technologies across China.

Latin America Blood Cancer Diagnostics Market 

Brazil is experiencing significant growth in the market

• Brazil is witnessing a gradual rise in blood cancer incidence, driven by improved disease reporting systems and increasing life expectancy. Leukemia and lymphoma diagnoses are becoming more common across both urban and semi-urban regions, highlighting a broader national disease burden.
• Additionally, the expanding patient population is fueling demand for timely and accurate diagnostic solutions. Healthcare providers are increasingly investing in hematology analyzers and molecular testing platforms to enhance diagnostic precision and overall clinical efficiency.
• Furthermore, the ongoing expansion of oncology services, coupled with stronger government focus on cancer care, is improving access to advanced diagnostics. Together, these factors are creating a supportive environment for sustained growth in the Brazilian blood cancer diagnostics industry.

Middle East and Africa Blood Cancer Diagnostics Market 

• Awareness of blood cancers is increasing in Saudi Arabia through national health initiatives and public outreach programs. Early screening is becoming a core component of preventive healthcare strategies.
• Additionally, government investments under Vision 2030 are strengthening oncology and diagnostic infrastructure nationwide. Access to advanced diagnostic testing has improved across major healthcare facilities.
• The growing focus on early diagnosis is increasing demand for blood cancer diagnostic technologies, thereby creating favorable growth conditions for the Saudi Arabia market.

Blood Cancer Diagnostics Market Share

• The major players in the global market include F. Hoffmann‑La Roche Ltd, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, and Sysmex Corporation. These companies collectively accounted for an estimated 55% share of the global blood cancer diagnostics industry in 2025, supported by strong penetration across hospitals and reference laboratories, broad hematology and molecular diagnostics portfolios, and well-established worldwide distribution and service networks.
• Key players in the market are increasingly prioritizing technological innovation and workflow optimization to improve diagnostic accuracy, turnaround time, and laboratory efficiency. Manufacturers are integrating advanced features such as next‑generation sequencing (NGS), AI‑driven pattern recognition, digital pathology, cloud‑based data management, and enhanced flow cytometry systems. These advancements support early and precise detection of leukemia, lymphoma, and multiple myeloma, reduce manual interpretation burden, and enable seamless data access across hospitals, diagnostic laboratories, and cancer research centers. Improved data visualization, automated reporting, and clinical decision‑support tools further strengthen product differentiation and adoption.
• Blood cancer diagnostics companies are expanding strategic collaborations with hospitals, oncology centers, hematologists, diagnostic laboratories, and academic research institutions to enhance clinical integration and product uptake. These partnerships support technology validation, clinician training, standardized diagnostic protocols, and incorporation into routine cancer care pathways. Manufacturers are also collaborating with public health agencies, biopharmaceutical companies, and genomic research programs to support precision oncology initiatives. Such collaborations are particularly impactful in high‑growth regions such as Asia Pacific, Latin America, and the Middle East, where investments in oncology diagnostics infrastructure are steadily increasing.
• Regional and emerging market players are focusing on developing cost‑effective and scalable blood cancer diagnostics solutions to address affordability and access challenges. Emphasis on localized manufacturing, simplified assay designs, and regional distribution networks enables broader penetration in price‑sensitive markets. By offering reliable, easy‑to‑use, and affordable diagnostic platforms including hematology analyzers, rapid molecular tests, and basic flow cytometry systems these manufacturers are expanding access to early cancer diagnosis across public hospitals, smaller laboratories, and underserved populations.

Blood Cancer Diagnostics Market Companies

Few of the prominent players operating in the blood cancer diagnostics industry include:

• Abbott Laboratories
• Adaptive Biotechnologies Corporation
• Agilent Technologies, Inc.
• Danaher Corporation
• Becton Dickinson and Company (BD)
• Bio‑Rad Laboratories, Inc.
• F. Hoffmann‑La Roche Ltd.
• GE Healthcare
• Guardant Health, Inc.
• Invivoscribe Technologies, Inc.
• Precipio Diagnostics
• QIAGEN N.V.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Exact Sciences Corporation

• F. Hoffmann La Roche Ltd

Roche strengthens its leadership in the blood cancer diagnostics market through its broad and deeply integrated diagnostic capabilities supporting the identification, classification, and monitoring of hematologic malignancies. The company’s strength lies in delivering clinically robust, standardized diagnostic solutions that enable accurate disease subtyping, prognostic assessment, and therapy guidance for leukemia, lymphoma, and myeloma. Its focus on quality, regulatory rigor, and consistency across laboratory workflows supports strong adoption in hospital‑based and reference laboratories. Ongoing investment in digital integration, data standardization, and precision‑medicine alignment reinforces Roche’s position as a strategic partner in advanced hematology diagnostics.

• Abbott Laboratories

Abbott reinforces its competitive positioning in the blood cancer diagnostics market by supporting both routine and specialized testing across the hematologic diagnostic pathway. The company’s strength lies in its ability to enable early detection through efficient blood‑based analysis while also supporting downstream confirmatory and characterization testing. Abbott emphasizes automation, workflow efficiency, and scalability, allowing laboratories to manage high testing volumes without compromising analytical reliability. Its strong global footprint, particularly in hospital and core laboratory environments, supports consistent adoption across diverse healthcare systems and contributes to its sustained relevance in hematologic oncology diagnostics.

• Thermo Fisher Scientific

Thermo Fisher Scientific plays a critical role in the blood cancer diagnostics market by enabling advanced molecular and genomic insights that support precision hematology. The company’s strength lies in facilitating comprehensive molecular characterization, mutation detection, and disease monitoring across leukemia, lymphoma, and myeloma. Its solutions are widely utilized in specialized diagnostic laboratories and cancer research institutes due to their analytical depth, flexibility, and compatibility with evolving clinical guidelines. A strong focus on automation, data analysis, and integrated laboratory workflows positions Thermo Fisher as a key enabler of next‑generation blood cancer diagnostics.

Blood Cancer Diagnostics Industry News:

• In May 2023, Cepheid, a subsidiary of Danaher Corporation, announced that it had received CE marking for the Xpert NPM1 Mutation test, a molecular in vitro diagnostic product designed to quantify mutant NPM1 mRNA transcripts (types A, B, and D in exon 12) in peripheral blood samples from patients with Acute Myeloid Leukemia (AML). This regulatory approval made the product available in Europe and boosted the company's revenue.

The blood cancer diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Assay kits and reagents

Market, By Test Type

• Blood test
• Imaging tests
• Biopsy
• Molecular test

Market, By Cancer Type

• Leukemia
• Lymphoma
• Myeloma

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Cancer research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE